691 Immune pressure in an advanced hepatocellular cancer patient following treatment with personalized neoantigen DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.